IceCure Reports Positive Results In Tumor-Freezing Breast Cancer Trial
Israeli biomedical company IceCure Medical, the developer of technology that freezes cancerous tumors, announced positive results this week from the company’s clinical trial for the use of its ProSense flagship system for cryoblation of small low-risk breast cancer tumors.
The ProSense is a liquid-nitrogen-based cryoablation system used in the treatment of patients with T1 invasive breast cancer or patients who are not suited for surgical alternatives for the treatment of breast cancer.
The system is one of two cryoablation systems developed by IceCure for treating malignant and benign tumors. The treatments involve streaming liquid nitrogen in a closed circuit and then freezing the tumor with a unique needle developed by IceCure. The company says the healthy tissue remains untouched.
Should COVID Shots for Teens Go to Developing Countries?
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Biden has delivered vaccines Now comes the hard part
washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.